Pasar al contenido principal

CD5 Y CD6 COMO DIANAS DE INMUNOMODULACION EN MODELOS EXPERIMENTALES DE AUTOINMUNIDAD E INFECCION

SAF2013-46151-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens

  • Delgado, Julio
  • Bielig, Torsten
  • Bonet, Lizette
  • Carnero-Montoro, Elena
  • Puente, Xose S.
  • Colomer, Dolors
  • Bosch, Elena
  • Campos, Elías
  • Lozano, Francisco
The work is supported by grants from Worldwide Cancer Research (14-1275), Fundació La Marató TV3 (201319-30), Spanish Ministerio de Economía y Competitividad (Plan Nacional I+D+i, SAF2013-46151-R; and International Cancer Genome Consortium for Chronic Lymphocytic Leukemia) co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, through Instituto de Salud Carlos III (ISCIII); and Red Temática de Investigación del Cáncer (RTIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD6 modulates thymocyte selection and peripheral T cell homeostasis

  • Orta-Mascaró, Marc
  • Álvarez, Pilar
  • Merino, Ramón
  • Martínez, Vanesa G.
  • Merino, Jesús
  • Lozano, Francisco
Orta-Mascaró et al., The CD6 glycoprotein is a lymphocyte surface receptor putatively involved in T cell development and activation. CD6 facilitates adhesion between T cells and antigen-presenting cells through its interaction with CD166/ALC AM (activated leukocyte cell adhesion molecule), and physically associates with the T cell receptor (TCR) at the center of the immunological synapse. However, its precise role during thymocyte development and peripheral T cell immune responses remains to be defined. Here, we analyze the in vivo consequences of CD6 deficiency. CD6-/- thymi showed a reduction in both CD4 and CD8 single-positive subsets, and double-positive thymocytes exhibited increased Ca2 mobilization to TCR cross-linking in vitro. Bone marrow chimera experiments revealed a T cell-autonomous selective disadvantage of CD6-/- T cells during development. The analysis of TCR-transgenic mice (OT-I and Marilyn) confirmed that abnormal T cell selection events occur in the absence of CD6. CD6-/- mice displayed increased frequencies of antigen-experienced peripheral T cells generated under certain levels of TCR signal strength or co-stimulation, such as effector/memory (CD4TEM and CD8TCM) and regulatory (T reg) T cells. The suppressive activity of CD6-/- T reg cells was diminished, and CD6-/- mice presented an exacerbated autoimmune response to collagen. Collectively, these data indicate that CD6 modulates the threshold for thymocyte selection and the generation and/or function of several peripheral T cell subpopulations, including T reg cells., This work is supported by grants from: Worldwide Cancer Research (14-1275) and Fundació La Marató TV3 (201319-30) to F. Lozano; Spanish Ministerio de Economía y Competitividad (Plan Nacional I+D+i) co-financed by European Development Regional Fund “A way to achieve Europe” to F. Lozano (SAF2013-46151-R), J. Merino (SAF2012-34059), R. Merino (SAF2014-55088-R), and R. Vicente (SAF2014- 52228-R); IPT2011-1527-010000 (associated to Fibrostatin SL) to J. Merino; and Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, European Research Council (FP7/2007–2013 grant no. 322465), and ANR grant Basilic to B. Malissen and M. Malissen. M. Orta-Mascaró, I. Simões, and E. Carreras are recipients of fellowships from Ministerio de Economía y Competitividad (BES-2011-048415), Fundação para a Ciência e a Tecnologia (SFRH/ BD/75738/2011), and European Community Seventh Framework Program (BIOTRACK, FP7/2007/2013;229673), respectively. National Institutes of Health grants to Velocigene at Regeneron Inc. (U01HG004085), and the CSD Consortium (U01HG004080) funded the generation of gene-targeted vectors and ES cells for 8,500 genes in the KOMP Program and archived and distributed by the KOMP Repository at UC Davis and CHORI (U42RR024244)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis

  • Martínez-Florensa, Mario
  • Consuegra-Fernández, Marta
  • Aranda, Fernando
  • Armiger-Borràs, Noelia
  • Di Scala, Marianna
  • Carrasco, Esther
  • Pachón, Jerónimo
  • Vila, Jordi
  • González-Aseguinolaza, Gloria
  • Lozano, Francisco
Sepsis still constitutes an unmet clinical need, which could benefit from novel adjunctive strategies to conventional antibiotic therapy. The soluble form of the scavenger-like human CD6 lymphocyte receptor (shCD6) binds to key pathogenic components from Gram-positive and -negative bacteria and shows time- and dose-dependent efficacy in mouse models of monobacterial sepsis. The objective of the present work was to demonstrate the effectiveness of infusing mouse and human sCD6 by different systemic routes, either alone or as adjunctive therapy to gold standard antibiotics, in a lethal model of polymicrobial sepsis. To this end, C57BL/6 mice undergoing high-grade septic shock induced by cecal ligation and puncture (CLP; ≥90% lethality) were infused via the intraperitoneal (i.p.) or intravenous (i.v.) route with shCD6 at different doses and time points, either alone or in combination with imipenem/cilastatin (I/C) at a dose of 33 mg/kg of body weight every 8 h. Significantly reduced mortality and proinflammatory cytokine levels were observed by i.p. infusion of a single shCD6 dose (1.25 mg/kg) 1 h pre- or post-CLP. When using the i.v. route, mice survival was significantly extended by starting shCD6 infusion at later time points post-CLP (up to 6 h after CLP). Significant adjunctive effects on mouse survival were observed by i.p. or i.v. infusion of shCD6 in combination with i.p. I/C post-CLP. Similar results were obtained in mice expressing high sustained levels (5 to 10 μg/ml) of mouse sCD6 in serum by means of transduction with hepatotropic adeno-associated virus (AAV). Taken together, the data support the conserved antibacterial effects of human and mouse sCD6 and their use as adjunctive therapy in experimental models of complex and severe polymicrobial sepsis., This work was supported by grants from the Spanish Ministerio de Economía y Competitividad (Plan Nacional de I+D+i, SAF2013-46151-R), Instituto de Salud Carlos III (ISCIII)-cofinanced by European Development Regional Fund “A way to achieve Europe” ERDF (Spanish Network for Research in Infectious Diseases, REIPI, RD12/0015/0018), and Fundació La Marató TV3 (201319-30-31). F.A. is recipient of a Sara Borrell fellowship (CD15/00016) from ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Erratum for Martínez-Florensa et al., “Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis”

  • Martínez-Florensa, Mario
  • Consuegra-Fernández, Marta
  • Aranda, Fernando
  • Armiger-Borràs, Noelia
  • Di Scala, Marianna
  • Carrasco, Esther
  • Pachón, Jerónimo
  • Vila, Jordi
  • González-Aseguinolaza, Gloria
  • Lozano, Francisco
Sepsis still constitutes an unmet clinical need, which could benefit from novel adjunctive strategies to conventional antibiotic therapy. The soluble form of the scavenger-like human CD6 lymphocyte receptor (shCD6) binds to key pathogenic components from Gram-positive and -negative bacteria and shows time- and dose-dependent efficacy in mouse models of monobacterial sepsis. The objective of the present work was to demonstrate the effectiveness of infusing mouse and human sCD6 by different systemic routes, either alone or as adjunctive therapy to gold standard antibiotics, in a lethal model of polymicrobial sepsis. To this end, C57BL/6 mice undergoing high-grade septic shock induced by cecal ligation and puncture (CLP; ≥90% lethality) were infused via the intraperitoneal (i.p.) or intravenous (i.v.) route with shCD6 at different doses and time points, either alone or in combination with imipenem/cilastatin (I/C) at a dose of 33 mg/kg of body weight every 8 h. Significantly reduced mortality and proinflammatory cytokine levels were observed by i.p. infusion of a single shCD6 dose (1.25 mg/kg) 1 h pre- or post-CLP. When using the i.v. route, mice survival was significantly extended by starting shCD6 infusion at later time points post-CLP (up to 6 h after CLP). Significant adjunctive effects on mouse survival were observed by i.p. or i.v. infusion of shCD6 in combination with i.p. I/C post-CLP. Similar results were obtained in mice expressing high sustained levels (5 to 10 μg/ml) of mouse sCD6 in serum by means of transduction with hepatotropic adeno-associated virus (AAV). Taken together, the data support the conserved antibacterial effects of human and mouse sCD6 and their use as adjunctive therapy in experimental models of complex and severe polymicrobial sepsis., This work was supported by grants from the Spanish Ministerio de Economía y Competitividad (Plan Nacional de I+D+i, SAF2013-46151-R), Instituto de Salud Carlos III (ISCIII)-cofinanced by European Development Regional Fund “A way to achieve Europe” ERDF (Spanish Network for Research in Infectious Diseases, REIPI, RD12/0015/0018), and Fundació La Marató TV3 (201319-30-31). F.A. is recipient of a Sara Borrell fellowship (CD15/00016) from ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger Receptors CD5 and CD6

  • Casadó-Llombart, Sergi
  • Velasco-de Andrés, María
  • Catalá, Cristina
  • Leyton-Pereira, Alejandra
  • Lozano, Francisco
  • Bosch, Elena
This article belongs to the Special Issue Scavenger Receptors in Inflammation., Pathogens are one of the main selective pressures that ancestral humans had to adapt to. Components of the immune response system have been preferential targets of natural selection in response to such pathogen-driven pressure. In turn, there is compelling evidence showing that positively selected immune gene variants conferring increased resistance to past or present infectious agents are today associated with increased risk for autoimmune or inflammatory disorders but decreased risk of cancer, the other side of the same coin. CD5 and CD6 are lymphocytic scavenger receptors at the interphase of the innate and adaptive immune responses since they are involved in both: (i) microbial-associated pattern recognition; and (ii) modulation of intracellular signals mediated by the clonotypic antigen-specific receptor present in T and B cells (TCR and BCR, respectively). Here, we review available information on CD5 and CD6 as targets of natural selection as well as on the role of CD5 and CD6 variation in autoimmunity and cancer., This research was funded by Spanish Ministerio de Economía y Competitividad (MINECO; SAF-2016-80535-R, PID2019-106658RB-I00 and PCIN-2015-070) co-financed by European Development Regional Fund (ERDF) “A way to achieve Europe”, Agencia Estatal de Investigación (AEI; PID2019-110933GB-I00/AEI/10.13039/501100011033 and CEX2018-000792-M) and Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR; 2017/SGR/1582 and 2017SGR00702) from Generalitat de Catalunya to F.L. and E.B. In addition, S.C.-L., M.V.-d.A., C.C. and A.L.-P. are recipients of fellowships from Ministerio de Educación, Cultura y Deporte (FPU15/02897) MINECO (BES-2014-069237; BES-2017-082107) and Chilean Agencia Nacional de Investigación y Desarrollo (ANID; 2018-72190154), respectively., Peer reviewed